Anaplasma phagocytophilum AnkA secreted by type IV secretion system is tyrosine phosphorylated by Abl-1 to facilitate infection

被引:144
作者
Lin, Mingqun
den Dulk-Ras, Amke
Hooykaas, Paul J. J.
Rikihisa, Yasuko
机构
[1] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA
[2] Leiden Univ, Inst Biol, Clusius Lab, NL-2333 AL Leiden, Netherlands
关键词
D O I
10.1111/j.1462-5822.2007.00985.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Anaplasma phagocytophilum, the agent of human granulocytic anaplasmosis, is an obligate intracellular bacterium of granulocytes. A. phagocytophilum specifically induces tyrosine phosphorylation of a 160 kDa protein (P160) in host cells. However, identity of P160, kinases involved, and effects of tyrosine phosphorylation on bacterial infection remain largely unknown. Here, we demonstrated through proteomic analysis that P160, an abundant and rapidly tyrosine-phosphorylated protein throughout infection, was AnkA of bacterial origin. Differential centrifugation and confocal microscopy revealed that AnkA was rarely retained within A. phagocytophilum or its inclusion, but localized mainly in the cytoplasm of infected cells. Using Cre recombinase reporter assay of Agrobacterium tumefaciens, we proved that AnkA could be secreted by VirB/D4-dependent type IV secretion (T4S) system. Yeast two-hybrid and coimmunoprecipitation analyses demonstrated that AnkA could bind to Abl-interactor 1 (Abi-1), an adaptor protein that interacts with Abl-1 tyrosine kinase, thus mediating AnkA phosphorylation. AnkA and Abl-1 were critical for bacterial infection, as infection was inhibited upon host cytoplasmic delivery of anti-AnkA antibody, Abl-1 knockdown with targeted siRNA, or treatment with a specific pharmacological inhibitor of Abl-1. These data establish AnkA as the first proven T4S substrate in members of obligate intracellular alpha-proteobacteria; furthermore, it demonstrated that AnkA plays an important role in facilitating intracellular infection by activating Abl-1 signalling pathway, and suggest a novel approach to treatment of human granulocytic anaplasmosis through inhibition of host cell signalling pathways.
引用
收藏
页码:2644 / 2657
页数:14
相关论文
共 44 条
[1]   Alveolar wall apoptosis causes lung destruction and emphysematous changes [J].
Aoshiba, K ;
Yokohori, N ;
Nagai, A .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2003, 28 (05) :555-562
[2]   Tyrosine-phosphorylated bacterial effector proteins: the enemies within [J].
Backert, S ;
Selbach, M .
TRENDS IN MICROBIOLOGY, 2005, 13 (10) :476-484
[3]   ABROGATION OF GAMMA-INTERFERON-INDUCED INHIBITION OF EHRLICHIA-CHAFFEENSIS INFECTION IN HUMAN MONOCYTES WITH IRON TRANSFERRIN [J].
BARNEWALL, RE ;
RIKIHISA, Y .
INFECTION AND IMMUNITY, 1994, 62 (11) :4804-4810
[4]   Pharmacology of imatinib (STI571) [J].
Buchdunger, E ;
O'Reilly, T ;
Wood, J .
EUROPEAN JOURNAL OF CANCER, 2002, 38 :S28-S36
[5]   Abl tyrosine kinases are required for infection by Shigella flexneri [J].
Burton, EA ;
Plattner, R ;
Pendergast, AM .
EMBO JOURNAL, 2003, 22 (20) :5471-5479
[6]   Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502
[7]   The versatile bacterial type IV secretion systems [J].
Cascales, E ;
Christie, PJ .
NATURE REVIEWS MICROBIOLOGY, 2003, 1 (02) :137-149
[8]   ankA:: an Ehrlichia phagocytophila group gene encoding a cytoplasmic protein antigen with ankyrin repeats [J].
Caturegli, P ;
Asanovich, KM ;
Walls, JJ ;
Bakken, JS ;
Madigan, JE ;
Popov, VL ;
Dumler, JS .
INFECTION AND IMMUNITY, 2000, 68 (09) :5277-5283
[9]   Protein phosphorylation on tyrosine in bacteria [J].
Cozzone, AJ ;
Grangeasse, C ;
Doublet, P ;
Duclos, B .
ARCHIVES OF MICROBIOLOGY, 2004, 181 (03) :171-181
[10]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042